In Washington, D.C., stakeholders in frontotemporal dementia came together to apply lessons learned from setbacks of Alzheimer’s drug development to the emerging field of therapy evaluation in FTD.
Luciano D’Adamio, M.D., Ph.D., professor of microbiology & immunology at Albert Einstein College of Medicine, has received a five-year, $3.6-million grant from the National Institutes of Health to continue his research into how APP is processed in the brain.
Last month, scientists gathered to powwow about where we are with FTD, DLB, and cerebrovascular disorders and how best to target research dollars to them. Researchers articulated funding priorities for each of these diseases, which will inform the next bypass budget, and, hopefully, the next funding allocation.
Long before Alzheimer’s disease can be diagnosed clinically, increasing difficulties building cognitive maps of new surroundings may herald the eventual clinical onset of the disorder, finds new research from Washington University in St. Louis.“These findings suggest that navigational tasks designed to assess a cognitive mapping strategy could represent a powerful new tool for detecting the very earliest Alzheimer’s disease-related changes in cognition,” said senior author Denise Head, associate professor of psychological and brain sciences in Arts & Sciences.
There are currently no medications available to specifically treat Lewy Body dementia (LBD), and patients are typically treated with medications for Alzheimer’s. FAU’s College of Medicine is spearheading the South Florida site for the first U.S. clinical trial for LBD, the second-most common dementia after Alzheimer’s.
The UK has seen a 20% fall in the incidence of dementia over the past two decades, according to new research from England, led by the University of Cambridge, leading to an estimated 40,000 fewer cases of dementia than previously predicted. However, the study, published today in Nature Communications, suggests that the dramatic change has been observed mainly in men.
Georgetown University researchers are reporting the first case of Alzheimer’s disease diagnosed in an HIV-positive individual. The finding in a 71-year-old man triggers a realization about HIV survivors now reaching the age when Alzheimer’s risk begins to escalate.
Scientists from the Florida campus of The Scripps Research Institute have identified a unique memory suppressor gene in the brain cells of Drosophila, the common fruit fly, a widely recognized substitute for human memory studies.
A $14.5 million NIA grant is supporting a new study led by researchers at Rush that aims to determine if an intervention known as the MIND diet can help prevent Alzheimer’s disease.
Tested in both mice and human cells and produced in the energy-producing mitochondria of cells, the proteins may lead to greater understanding of aging-related diseases from diabetes to Alzheimer's to cancer.
A recent study has demonstrated that, beyond causing memory problems, Alzheimer’s disease also impairs visual face perception. This finding may help families better understand their loved one's inevitable difficulties and lead to new avenues to postpone this painful aspect of the disease, such as the recognition of particular facial traits or voice recognition.
The blood-brain barrier has stymied direct treatment of brain disorders. In a recently published study, a Cornell researcher reports finding a way to pass therapeutics through the barrier, using readily-available agents.
Research from the Icahn School of Medicine at Mount Sinai published in the journal Alzheimer’s and Dementia suggests that Alzheimer’s disease (AD) impairs insulin signaling in the portion of the brain responsible for regulating metabolism, making a person with AD more likely to develop diabetes
To understand how people can live longer throughout the world, researchers at University of California, San Diego School of Medicine have teamed up with colleagues at University of Rome La Sapienza to study a group of 300 citizens, all over 100 years old, living in a remote Italian village nestled between the ocean and mountains on the country’s coast.
Every day, more than 15 million unpaid caregivers provide care to people with Alzheimer’s disease, with little outside support and often at the risk of their own health.
Cell’s protein factory may hold key to stalling cognitive decline.
At least half of Parkinson’s disease patients experience psychosis at some point during the course of their illness, and physicians commonly prescribe antipsychotic drugs, such as quetiapine, to treat the condition. However, a new study by researchers at the Perelman School of Medicine at the University of Pennsylvania, the University of Michigan Medical School, and the Philadelphia and Ann Arbor Veterans Affairs (VA) Medical Centers and suggests that these drugs may do significantly more harm in a subset of patients.
An international team of investigators led by experts at the Perelman School of Medicine at the University of Pennsylvania has been awarded a nearly $3 million, five-year grant from the National Institute of Neurological Disorders and Stroke (NINDS) to establish diagnostic criteria for chronic traumatic encephalopathy (CTE).
MINNEAPOLIS – Women may have a better memory for words than men despite evidence of similar levels of shrinkage in areas of the brain that show the earliest signs of Alzheimer’s disease, according to a study published in the March 16, 2016, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Could an unhealthy diet and lack of exercise be making you age faster? Researchers at Mayo Clinic believe there is a link between these modifiable lifestyle factors and the biological processes of aging. In a recent study, researchers demonstrated that a poor diet and lack of exercise accelerated the onset of cellular senescence and, in turn, age-related conditions in mice. Results appear today in Diabetes.
A new study shows that a variety of physical activities from walking to gardening and dancing can improve brain volume and cut the risk of Alzheimer's disease by 50%.
A new study, jointly led by the University of Southampton and King’s College London, has found a link between gum disease and greater rates of cognitive decline in people with early stages of Alzheimer’s Disease.
Evidence of grid cell activity has been seen in healthy volunteers asked to imagine moving through an environment in new UCL research, which could help to explain why people with Alzheimer's can have problems imagining as well as remembering things.
Anyone caring for a loved one with Alzheimer’s disease likely can relate to former first lady Nancy Reagan, who called the illness suffered by former President Ronald Reagan “a truly long, long goodbye.”
JAX research provides insight into the role of the western diet in Alzheimer’s disease.
NYU Hartford researchers recently developed the Dementia Symptom Management at Home (DSM-H) program to help home healthcare agencies to improve the quality of care they provide to patients living with dementia (PLWD) and reduce caregiver stress and burnout.
Keeping the brain active with social activities and using a computer may help older adults reduce their risk of developing memory and thinking problems, according to a study released today that will be presented at the American Academy of Neurology’s 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.
New research led by scientists at UC Berkeley shows for the first time that PET scans can track the progressive stages of Alzheimer’s disease in cognitively normal adults, a key advance in the early diagnosis and staging of the neurodegenerative disorder.
Participating dementia specialists may now enroll patients to participate in the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study at IDEAS-Study.org.
UT Southwestern Medical Center has joined a consortium of seven leading universities to develop new technologies to improve memory in people with traumatic brain injury, mild cognitive impairment, epilepsy, and Alzheimer’s disease.
The Lewy Body Dementia Association (LBDA) Board of Directors has named Kathleen Anduze, the recipient of the newly re-named LBDA Dorothy Mangurian Volunteer of the Year Award.
A tiny protein known as an “amyloid beta” acts like Jekyll and Hyde in mysterious ways within the human body. Outsized human suffering is linked to this otherwise tiny, innocuous-looking molecule, as it is suspected to be a key player in the neurodegenerative mechanisms underlying Alzheimer’s disease. Amyloid beta molecules appear to become toxic within our bodies when they make contact with each other and form small bundles. Oddly, they may become less toxic again as the bundles grow larger in size and form ordered fibrillary plaque deposits. This begs the question: What’s different about these bundles than the single protein molecule and the fibrils?
The blueberry, already labeled a “super fruit” for its power to potentially lower the risk of heart disease and cancer, also could be another weapon in the war against Alzheimer’s disease. The researchers present their work today at the 251st National Meeting & Exposition of the American Chemical Society.
Using a drug compound created to treat cancer, University of California, Irvine neurobiologists have disarmed the brain’s response to the distinctive beta-amyloid plaques that are the hallmark of Alzheimer’s disease.
People who keep mentally and physically healthy in middle age may help stave off the symptoms of Alzheimer’s disease, but the activity does not affect the underlying disease changes in the brain for most people, according to a study published in the February 24 online edition of Neurology®, the medical journal of the American Academy of Neurology.
Keeping the mind active may delay symptoms of Alzheimer’s disease; however, the activity does not change the underlying disease in the brain for most people, according to a study published today in the online edition of Neurology.
Many patients showing signs of dementia are quickly diagnosed with Alzheimer’s disease when they might actually suffer from frontotemporal dementia, delaying the appropriate treatment for them.
Dr. Brad Pfeiffer, Assistant Professor of Neuroscience and a Southwestern Medical Foundation Scholar in Biomedical Research at UT Southwestern Medical Center, has been selected as a 2016 Alfred P. Sloan Foundation Research Fellow in Neuroscience.
Immune cells that normally help us fight off bacterial and viral infections may play a far greater role in Alzheimer’s disease than originally thought, according to University of California, Irvine neurobiologists with the Sue & Bill Gross Stem Cell Research Center and the Institute for Memory Impairments and Neurological Disorders.
A chemist at Washington University in St. Louis hopes to develop bifunctional compounds that can be both therapeutic and diagnostic agents for Alzheimer’s disease. In the first role, they would block the metal-mediated formation of amyloid beta oligomers; in the second, they would be loaded with a long-lived radioistope (Cu-64) and employed as PET imaging agents.
A free, open online course on rare forms of dementia aims to spread knowledge while harnessing social learning.
Essential for maintaining cognitive function as a person ages, the tiny locus coeruleus region of the brain is vulnerable to toxins and infection.
Studies report no reduction in the amyloid-β peptide or the plaques it forms. Hints of efficacy came from four people free of the ApoE4 risk gene for AD, and one patient who was on it for nearly two years. Meanwhile, scientists uncovered a new mechanism of action for bexarotene. Researchers wonder what’s going on.
It may start with a simple word you can’t pronounce. Your tongue and lips stumble, and gibberish comes out. Misspeaking might draw a chuckle from family and friends. But, then, it keeps happening. Progressively, more and more speech is lost. Some patients eventually become mute from primary progressive apraxia of speech, a disorder related to degenerative neurologic disease.
American Association for the Advancement of Science 2016 Annual Meeting
Scientists from the Florida campus of The Scripps Research Institute have won nearly $1.7 million from the National Institutes of Health’s National Institute of Neurological Disorders and Stroke to investigate the mechanisms that contribute to Huntington’s disease.
University students and residents of senior housing come together in an award-winning project that encourages storytelling collaborations.
Inhibiting the Rho kinases ROCK1 and ROCK2 with fasudil, a drug approved in China and Japan, stimulates tau autophagy in cell culture and flies.
New research from the University of Guelph on the brain and memory could help in developing therapies for people with schizophrenia and Alzheimer’s disease.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right